192 related articles for article (PubMed ID: 29558957)
1. Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
Xu T; Li D; He Y; Zhang F; Qiao M; Chen Y
World J Surg Oncol; 2018 Mar; 16(1):60. PubMed ID: 29558957
[TBL] [Abstract][Full Text] [Related]
2. Metformin use improves the survival of diabetic combined small-cell lung cancer patients.
Kong F; Gao F; Liu H; Chen L; Zheng R; Yu J; Li X; Liu G; Jia Y
Tumour Biol; 2015 Sep; 36(10):8101-6. PubMed ID: 25983003
[TBL] [Abstract][Full Text] [Related]
3. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
Medairos RA; Clark J; Holoubek S; Kubasiak JC; Pithadia R; Hamid F; Chmielewski GW; Warren WH; Basu S; Borgia JA; Liptay MJ; Seder CW
J Thorac Cardiovasc Surg; 2016 Jul; 152(1):55-61.e1. PubMed ID: 27157918
[TBL] [Abstract][Full Text] [Related]
4. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
6. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
8. Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum.
Wen-Xiu X; Xiao-Wei Z; Hai-Ying D; Ying-Hui T; Si-Si K; Xiao-Fang Z; Huang P
Medicine (Baltimore); 2018 Dec; 97(51):e13652. PubMed ID: 30572481
[TBL] [Abstract][Full Text] [Related]
9. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.
Parikh AB; Kozuch P; Rohs N; Becker DJ; Levy BP
Invest New Drugs; 2017 Dec; 35(6):813-819. PubMed ID: 28936567
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Xu T; Liang G; Yang L; Zhang F
Clin Transl Oncol; 2015 Oct; 17(10):819-24. PubMed ID: 26063645
[TBL] [Abstract][Full Text] [Related]
12. Metformin use and lung cancer survival: a population-based study in Norway.
Brancher S; Støer NC; Weiderpass E; Damhuis RAM; Johannesen TB; Botteri E; Strand TE
Br J Cancer; 2021 Mar; 124(5):1018-1025. PubMed ID: 33262518
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
14. Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system.
Lin J; Gill A; Zahm SH; Carter CA; Shriver CD; Nations JA; Anderson WF; McGlynn KA; Zhu K
Int J Cancer; 2017 Jul; 141(2):254-263. PubMed ID: 28380674
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival analysis of patients with non-small cell lung cancer complicated with type 2 diabetes mellitus.
Wang G; Li X; Xiong R; Wu H; Xu M; Xie M
Thorac Cancer; 2020 May; 11(5):1309-1318. PubMed ID: 32190995
[TBL] [Abstract][Full Text] [Related]
16. Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.
Arrieta O; Varela-Santoyo E; Soto-Perez-de-Celis E; Sánchez-Reyes R; De la Torre-Vallejo M; Muñiz-Hernández S; Cardona AF
BMC Cancer; 2016 Aug; 16():633. PubMed ID: 27519177
[TBL] [Abstract][Full Text] [Related]
17. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.
Wink KC; Belderbos JS; Dieleman EM; Rossi M; Rasch CR; Damhuis RA; Houben RM; Troost EG
Radiother Oncol; 2016 Mar; 118(3):453-9. PubMed ID: 26861738
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
Hu X; Xiong H; Chen W; Huang L; Mao T; Yang L; Wang C; Huang D; Wang Z; Yu J; Shu Y; Xia K; Su T
Surg Oncol; 2020 Dec; 35():453-459. PubMed ID: 33065527
[TBL] [Abstract][Full Text] [Related]
19. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for resected non-small cell lung cancer in patients with type 2 diabetes mellitus.
Yu WS; Lee CY; Park SY; Suh JW; Narm KS; Kim DJ; Chung KY; Lee JG
J Surg Oncol; 2018 Apr; 117(5):985-993. PubMed ID: 29409112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
